Cerebral toxoplasmosis in a patient leads to diagnosis of AIDS

Alireza Soleimani¹, Amir Bairami²*

¹Department of Infectious Disease, Madani Hospital, Alborz University of Medical Sciences, Karaj, Iran
²Department of Medical Parasitology and Mycology, School of Medicine, Alborz University of Medical Sciences, Karaj, Iran

ARTICLE INFO

Article history:
Received 24 Sep 2014
Received in revised form 16 Oct 2014, 2nd revised form 15 Apr 2015
Accepted 25 May 2015
Available online 7 Jul 2015

Keywords:
Toxoplasmosis
Cerebral
AIDS

ABSTRACT

Toxoplasmosis is an infection caused by the intracellular protozoan parasite, with a worldwide distribution from 30%–75% seroprevalence in different countries. In patient with immunosuppression such as AIDS, the parasite can be reactivated and causes the disease. We report on the case of a 36–year–old man admitted to Madani Hospital with imbalance and loss of consciousness. He has been suffering headache, impaired speech and inability to walk since two weeks ago. In magnetic resonance imaging multiple space occupying lesions in bilateral cerebral hemispheres with ring enhancement after contrast injection were seen. HIV test for HIV-1 was reactive, Toxoplasma serology was revealed raised immunoglobulin G antibody levels of 650 IU/mL. Cerebral toxoplasmosis in this patient leads to diagnosis of HIV infection at advanced stage. The patient treated successfully with alternative drug but we need more activity in education of high risk people to get tested for HIV in our country, Iran.

1. Introduction

Toxoplasmosis is an infection caused by the intracellular protozoan parasite, with a worldwide distribution from 30%–75% seroprevalence in different countries[1]. Among person with normal immune response, the primary infection is often asymptomatic and latent infection will be started sequentially, on the other hand, the disease is self limited[2]. But in patient with immunosuppression such as AIDS, the parasite can be reactivated and causes the disease[3]. Delay in diagnosis of HIV infection is a usual complication cause momentous morbidity and mortality rate in HIV positive patient even after initiating antiretroviral therapy[4]. Reactivation of toxoplasma infection in seropositive patients with AIDS without effective prophylaxis is 30% approximately. The most common reactivation form is toxoplasmic encephalitis[5]. This paper is reporting a case of cerebral toxoplasmosis leading to diagnosis of AIDS in an undiagnosed AIDS patient.

2. Case report

A 36–year–old man was admitted to Madani Hospital with imbalance and loss of consciousness. At the emergency department, the patient was clinically assessed and transferred to intensive care unit for further management. He has been suffering headache, impaired speech and inability to walk since two weeks ago.

On examination, he was febrile to 38 °C, but his other vital signs were stable. Laboratory tests resulted in white blood cell: 1500/mm³, haemoglobin: 12.6 g/dL, plateletcount: 137 000/mm³, blood glucose level: 132 mg/dL, serum creatinine: 0.6 mg/dL, serum sodium (Na⁺): 139 mmol/L, serum potassium (K⁺): 3.8 mmol/L. Liver function tests were within normal limits.

Magnetic resonance imaging (MRI) was performed because of loss of consciousness. There were multiple space occupying lesions in bilateral cerebral hemispheres with ring enhancement after contrast injection. Most of the lesions were located in right posterior parietal, rostrum of corpus callosum and left anterior temporal regions. Shift to the left side and early signs of transtentorial herniation were seen in right side. There were a few small lesions also in cerebellar hemispheres without contrast (Figure 1).
Clinical manifestation, multiple ring enhancing lesions in MRI and history of intravenous drug user approached us to find an underlying immunodeficiency syndrome in the patient. According to this reasons HIV-Ab and toxoplasma immunoglobulin G (IgG)-Ab were checked. HIV test for HIV-1 was reactive by ELISA and was confirmed by Western blot test. After one week the CD4 cell count of patient was ready and 60 cell/μL. Toxoplasma serology was revealed raised IgG antibody levels of 650 IU/mL.

For the patient with a possible diagnosis of cerebral toxoplasmosis in AIDS, the trial treatment with intravenous cotrimoxazole was begun. We also used dexamethasone cause of radiographic evidence of midline shift for 48 h. Antiretroviral therapy was begun after one week too. Careful daily neurologic examination showed that the patient’s level of consciousness was improved after one week of treatment, and ataxia and dysarthria were resolved after two weeks. At 21st day of admission another MRI of brain was done in which near total disappearance of cerebral toxoplasmosis lesions was seen. The treatment was continued for 6 weeks. Fortunately, in this time there was no any side effect or inflammatory reaction with treatment. He was advised to continue antiretroviral drugs and cotrimoxazole prophylaxis.

3. Discussion

Cerebral toxoplasmosis is one of the opportunistic infections in patients with AIDS specially in patients with CD4+ T cell counts below 200/μL, but its incidence is decreasing after starting antiretroviral drugs[6]. In mentioned patient although there was a high risk of HIV infection but he has not been tested and it resulted in progressing of his HIV infection to the advanced stage and reactivation of toxoplasmosis. The clinical presentations of cerebral toxoplasmosis in patients with HIV infection are fever, headache and focal neurological deficits such as seizure, hemiparesis or aphasia. Confusion, dementia, lethargy and at last coma are the other manifestations[7].

The diagnosis is usually based on the CT scan or MRI findings of multiple enhancing lesions in seropositive for toxoplasmosis, although finding in MRI is more useful[8]. The differential diagnosis of single or multiple enhancing mass lesions in patient with HIV-infection are contain of cerebral toxoplasmosis, primary central nervous system lymphoma, tuberculosis or fungal or bacterial abscesses[9]. Toxoplasma IgG antibodies is seropositive in approximately 97% of patient with cerebral toxoplasmosis[10]. Toxoplasma IgG antibody levels in this patient was 650 IU/mL. However, cerebrospinal fluid examination can help in differential diagnosis of brain lesion in HIV patient, but in this patient cause of mass effect of lesions, lumbar puncture was contraindicated. The definitive diagnostic procedure in cerebral toxoplasmosis is brain biopsy. However, this procedure is usually reserved for the patient who has failed 2-4 weeks of empirical. Therefore, we decided to start the empirical treatment of toxoplasmosis based on the imaging finding. The choice of combination drug in these patients is pyrimethamine plus sulfadiazine plus leucovorin[11]. Pyrimethamine plus clindamycin can be used in patients who cannot take sulfadiazine due to intolerance or allergy in previous usage.

Cotrimoxazol may be an alternative drug, particularly in critically ill patients by intravenous administration of trimetoprim(10 mg/kg/d) + sulfametoxazol (50 mg/kg/d)[12]. Patient in present report was successfully treated with cotrimoxazole (trimetoprim-sulfametoxazol).

Cerebral toxoplasmosis in this patient leads to diagnosis of HIV infection at advanced stage. However, we treated the patient successfully with alternative drug but we need more activity in education of high risk people to get tested for HIV in our country, Iran. This leads to good response to treatment, decreasing the risk of transmission to others and preventing to progress of HIV infection to advanced stage with opportunistic infection such as cerebral toxoplasmosis.

Conflict of interest statement

We declare that we have no conflict of interest.

References

[1] Muluye D, Wondimeneh Y, Belyhun Y, Moges F, Endris M, Getachew Ferede G, et al. Prevalence of Toxoplasma gondii and associated risk factors among people living with HIV at Gondar University Hospital, Northwest Ethiopia. Tropical Med 2013; doi: 10.1155/2013/123858.

[2] Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. 18th ed. USA: McGraw-Hill; 2012. p. 1722-9.

[3] Kodym P, Maly M, Beran O, Jilich D, Rozsvpály H, Machala L, et al. Incidence, immunological and clinical characteristics of reactivation of latent Toxoplasma gondii infection in HIV-infected patients. Epidemiol Infect 2015; 143(3): 600-7.

[4] Wolbers M, Bucher HC, Furrer H, Rickenbach M, Cavassini M, Weber R, et al. Delayed diagnosis of HIV infection and late initiation of antiretroviral therapy in the Swiss HIV cohort study. HIV Med 2008; 9: 397-405.

[5] Oshinaike OO, Okubadejo NU, Ojini FI, DanesiMA. A preliminary study of the frequency of focal neurological deficits in HIV/AIDS patients seropositive for Toxoplasma gondii IgG in Lagos, Nigeria. Nig J Hosp Med 2010; 20(3): 104-7.

[6] Naqi R, Azizemuddin M, Ahsan H. Cerebral toxoplasmosis in a patient with acquired immunodeficiency syndrome. J Pak Med Assoc 2010; 60: 316-8.

[7] Kloska SP, Hrusstetd IW, Schlegel PM, Anneken K, Evers S, Fischbach R, et al. [Magnetic resonance imaging findings of the brain in adult HIV and AIDS patients]. Rofo 2008; 180: 21-9. German.

[8] Shyambabu C, Satishchandra P, Mahadevan A, Pillai Shibu V, Ravishankar S, Sidappa N, et al. Usefulness of stereotactic biopsy and neuroimaging in management of HIV-1 Clade C associated focal brain lesions with special focus on cerebral toxoplasmosis. Clin Neurol Neurosurg 2013; 115(7): 995-1002.

[9] Garg RK, Sinha MK. Multiple ring-enhancing lesions of the brain. J Postgrad Med 2010; 56(4): 307-16.

[10] Skiest DJ, Erdman W, Chang WE, Oz OK, Ware A, Fleckenstein J. SPECT thallium-201 combined with Toxoplasma serology for the presumptive diagnosis of focal central nervous system mass lesions in patients with AIDS. J Infect 2000; 40(3): 274-81.

[11] Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomp Rev 2009; 58: 1-207.

[12] Rajapakse S, Chirishan Shivthan M, Samaranayake N, Rodrigo C, Deepika Fernando S. Antibiotics for human toxoplasmosis: a systematic review of randomized trials. Pathog Glob Health 2013; 107(4): 162-9.